Bangalore-based biotech company Connexios Life Sciences, and Boehringer Ingelheim announced an exclusive global research collaboration agreement for AMPK for the treatment of patients with type-2 diabetes.
The terms and financial details of the collaboration were undisclosed.
As part of the agreement, Boehringer Ingelheim obtains global rights to CNX-012, Connexios Life Sciences' program on AMPK activators.
The program includes CNX-570 and other compounds which are in early pre-clinical development.
Boehringer Ingelheim will be responsible for all further development and commercialization of the candidates from the AMPK program.